Halozyme and Incyte Join Forces to Improve Cancer Drug Delivery
SAN DIEGO, July 20, 2026 Halozyme Therapeutics has entered into a global collaboration and license agreement with Incyte to...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
SAN DIEGO, July 20, 2026 Halozyme Therapeutics has entered into a global collaboration and license agreement with Incyte to...
SEATTLE, July 20, 2026 The Society of NeuroInterventional Surgery (SNIS) has unveiled a series of groundbreaking scientific presentations for...
SILVER SPRING, Maryland, June 12, 2026 The U.S. Food and Drug Administration (FDA) has cleared the Dexcom Stelo Glucose...
FLORENCE, Italy and NEW YORK, June 14, 2026 Menarini Group and its oncology-focused subsidiary Stemline Therapeutics have announced promising...
NEWTON, Mass., June 1, 2026 Karyopharm Therapeutics has announced that it will host an investor conference call featuring leading...
